Indole–hydrazone hybrid derivatives as emerging therapeutics for enhanced skin cancer therapy: molecular design, biological evaluation and nanoliposomal delivery
RSC Pharmaceutics · 2026
DOI: 10.1039/d6pm00325g ↗Kurz gefasst
Fachartikel in der Zeitschrift RSC Pharmaceutics, 2026. Verfasst von Saleem Akbar und 7 weiteren Autor:innen. Die Arbeit nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Indian Council of Medical Research.
Abstract (Originalsprache)
To advance skin cancer therapeutics, a series of indole–hydrazone derivatives (5a–5l) was synthesized via the hydrazone condensation reaction and formulation development of 5l -based nanoliposomal gel (GEL4).
Förderung
- Indian Council of Medical Research
Zitieren
APA
Akbar, S., Noor, A., Das, S., Kumari, S., Rahaman, S. B., Khalilullah, H., Ahmed, B., & Dewangan, R. P. (2026). Indole–hydrazone hybrid derivatives as emerging therapeutics for enhanced skin cancer therapy: molecular design, biological evaluation and nanoliposomal delivery. RSC Pharmaceutics. https://doi.org/10.1039/d6pm00325g
Vancouver
Akbar S, Noor A, Das S, Kumari S, Rahaman SB, Khalilullah H, et al. Indole–hydrazone hybrid derivatives as emerging therapeutics for enhanced skin cancer therapy: molecular design, biological evaluation and nanoliposomal delivery. RSC Pharmaceutics. 2026. doi:10.1039/d6pm00325g
BibTeX
@article{Akbar2026,
author = {Akbar, Saleem and Noor, Afeefa and Das, Subham and Kumari, Shalini and Rahaman, Sk Batin and Khalilullah, Habibullah and Ahmed, Bahar and Dewangan, Rikeshwer Prasad},
title = {Indole–hydrazone hybrid derivatives as emerging therapeutics for enhanced skin cancer therapy: molecular design, biological evaluation and nanoliposomal delivery},
journal = {RSC Pharmaceutics},
year = {2026},
doi = {10.1039/d6pm00325g}
}
EUVIMED